These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34079085)

  • 21. Wnt/β-catenin signaling as an emerging potential key pharmacological target in cholangiocarcinoma.
    Zhang GF; Qiu L; Yang SL; Wu JC; Liu TJ
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32140709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mitochondrial transplantation inhibits cholangiocarcinoma cells growth by balancing oxidative stress tolerance through PTEN/PI3K/AKT signaling pathway.
    Liu X; Zhang Y; Yang X; Zhang Y; Liu Y; Wang L; Yi T; Yuan J; Wen W; Jian Y
    Tissue Cell; 2023 Dec; 85():102243. PubMed ID: 37865041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells.
    Deng S; Zhang L; Li J; Jin Y; Wang J
    Tissue Cell; 2022 Jun; 76():101756. PubMed ID: 35217388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
    Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
    Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
    Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
    Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SPARC induces M2 polarization of macrophages to promote proliferation, migration, and angiogenesis of cholangiocarcinoma cells.
    Deng SK; Jin Y; Jin Y; Wang JF
    Neoplasma; 2022 Sep; 69(5):1101-1107. PubMed ID: 35951457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newly developed humanized anti-CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1-CKAP4 signaling.
    Sada R; Yamamoto H; Matsumoto S; Harada A; Kikuchi A
    Cancer Sci; 2024 Oct; 115(10):3358-3369. PubMed ID: 39118263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Targets and Signaling Pathways in Cholangiocarcinoma: A Systematic Review.
    Idris R; Chaijaroenkul W; Na-Bangchang K
    Asian Pac J Cancer Prev; 2023 Mar; 24(3):741-751. PubMed ID: 36974526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of ECM1 contributes to migration and invasion in cholangiocarcinoma cell.
    Xiong GP; Zhang JX; Gu SP; Wu YB; Liu JF
    Neoplasma; 2012; 59(4):409-15. PubMed ID: 22489696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
    Asukai K; Kawamoto K; Eguchi H; Konno M; Asai A; Iwagami Y; Yamada D; Asaoka T; Noda T; Wada H; Gotoh K; Nishida N; Satoh T; Doki Y; Mori M; Ishii H
    Ann Surg Oncol; 2017 Aug; 24(8):2344-2352. PubMed ID: 28560603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway.
    Leng K; Xu Y; Kang P; Qin W; Cai H; Wang H; Ji D; Jiang X; Li J; Li Z; Huang L; Zhong X; Sun X; Wang Z; Cui Y
    Cell Death Dis; 2019 Mar; 10(4):262. PubMed ID: 30886152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway.
    Thongpon P; Intuyod K; Chomwong S; Pongking T; Klungsaeng S; Muisuk K; Charoenram N; Sitthirach C; Thanan R; Pinlaor P; Pinlaor S
    Sci Rep; 2024 Jul; 14(1):16059. PubMed ID: 38992159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
    Cho S; Lee TS; Song IH; Kim AR; Lee YJ; Kim H; Hwang H; Jeong MS; Kang SG; Hong HJ
    PLoS One; 2017; 12(2):e0170078. PubMed ID: 28166242
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
    Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
    Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy.
    Kikuchi A; Fumoto K; Kimura H
    Br J Pharmacol; 2017 Dec; 174(24):4651-4665. PubMed ID: 28514532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic palmitoylation controls the microdomain localization of the DKK1 receptors CKAP4 and LRP6.
    Sada R; Kimura H; Fukata Y; Fukata M; Yamamoto H; Kikuchi A
    Sci Signal; 2019 Nov; 12(608):. PubMed ID: 31744930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery.
    Shi RY; Yang XR; Shen QJ; Yang LX; Xu Y; Qiu SJ; Sun YF; Zhang X; Wang Z; Zhu K; Qin WX; Tang ZY; Fan J; Zhou J
    Cancer; 2013 Mar; 119(5):993-1003. PubMed ID: 23132676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
    Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
    Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.